Integrins clearly play a key role in regulating both mitogenic signalling and cell migration. Thus integrins modulate the efficiency of the Erk (extracellular-signal-regulated kinase)/MAP kinase (mitogen-activated protein kinase) pathway, acting at several distinct levels. We have shown that both cAMP-dependent protein kinase and PAKs (p21-activated kinases) play a role in integrin regulation of the Erk pathway, acting primarily at the level of Raf-1. Integrins and PAKs also play a role in the control of cell migration. Thus we have discovered a novel protein that links the α5β1 integrin to migration controlled by Rho-family GTPases. This protein, termed Nischarin, is a large cytosolic macromolecule that is not related to well-known protein families. The N-terminus of Nischarin interacts with a short segment of the cytoplasmic domain of the α5 integrin subunit. Overexpression of Nischarin alters actin organization and inhibits Rac-driven cell migration and tumour cell invasion. Use of effector domain mutants of Rac suggest that Nischarin acts downstream of Rac, probably at the level of PAK-family kinases. These studies emphasize the intricate connection between integrins and Rho-family GTPases and their effectors in controlling both mitogenesis and migration.
Introduction
Integrins play a key structural role in cells, spanning the membrane to link the extracellular matrix to the actin cytoskeleton. In addition to this architectural function, work over the last decade has shown that integrins are also important initiators and modulators of signal-transduction processes. In this paper, we discuss two aspects of the role of integrins in signalling. We first examine the mechanisms underlying integrin regulation of the Erk (extracellular-signalregulated kinase)/MAP kinase (mitogen-activated protein kinase) cascade. Then, recent work on an integrin-associated protein that has a profound influence on cell migration is described.
Integrins and the MAP kinase cascade
The 'classic' MAP kinase cascade begins with activation and autophosphorylation of RTK (receptor tyrosine kinase) on the cell surface [1] . This creates phosphotyrosyl binding sites for SH2-domain (Src homology 2 domain) adaptor proteins such as Grb2 and Shc, which in turn can recruit other proteins such as SOS, a partner of Grb2 that is an exchange factor for Ras GTPase. Activation of Ras at the membrane by SOS leads to the recruitment of Raf-1 into the membrane and its subsequent activation. Raf-1 is the first kinase in the intracytoplasmic signalling pathway leading to Erk. Raf-1 subsequently phosphorylates and activates MEK1 (MAP kinase/Erk kinase) and MEK2, which can then phosphorylate Erk1 and Erk2 on critical TEY motifs, leading to the activation of Erks. Activated Erk is released from MEK and migrates to the nucleus, where it can phosphorylate its targets, particularly members of the ETS (E twenty-six) family of transcription factors, such as ELK-1. Activation of key transcriptional targets then drives the cell into the cell cycle, leading eventually to cell replication.
Integrins play an important role in regulating the efficiency of the RTK/Ras/Erk pathway [2, 3] . This issue has largely been explored by comparing the performance of the signalling pathway in cells that are anchored to the ECM (extracellular matrix) via their integrins and cells that are held in suspension and thus lack integrin engagement with ligands. Integrin regulation occurs at three (or more) different loci within the Erk pathway ( Figure 1 ). First, in some cell systems, integrin engagement with ligands enhances the activation and autophosphorylation of the RTKs [4] [5] [6] . Secondly, integrin engagement enhances the efficiency of the cytoplasmic cascade comprising Raf-1, MEK and Erk. This aspect of regulation has been suggested to take place either at the level of Raf-1, at MEK1 or at both loci [7] [8] [9] . Finally, it has become clear that integrin engagement is necessary for trafficking of activated Erk from the cytoplasm to the nucleus [10] . Interestingly, this seems to be unique to Erk and does not apply to JNK (c-Jun N-terminal kinase) or p38 MAP kinase [11] .
Recent work from our laboratory has focused on how integrin-mediated cell anchorage influences the function of the cytosolic signalling module comprised of Raf-1, MEK and Erk. Interestingly, we have found an important role for two other kinases, namely cyclic nucleotide-dependent PKA (protein kinase A) and PAKs (p21-activated kinases). Early studies suggested that the activation of Raf-1 was compromised in cells deprived of integrin-mediated anchorage [7] . This is similar to the situation in cells where PKA is activated [12] . Thus we examined whether anchorage regulation of Raf-1 involved PKA [13] . This was done by using dominant-negative versions of PKA or by expressing a specific peptide inhibitor of PKA. We found that blocking PKA activity could significantly 'rescue' activation of Raf-1 and Erk in cells held in suspension. We also found that shifting cells from an integrin-anchored state to suspension caused a substantial but transient activation of PKA. The precise mechanism of PKA activation under these circumstances is not clear; however, there is evidence that changes in anchorage and cytoskeletal integrity can affect cAMP levels by a mechanism that involves arachidonic acid metabolites [14] . These observations implicate PKA as a factor in the anchorage regulation of the Erk pathway.
It was evident from other studies that PAK plays an important permissive role in the activation of Raf-1 and MEK [15, 16] . It also became clear that PAK activity was regulated by integrin-mediated cell anchorage [17] . Thus we decided to test whether PAK (PAK1) also had a role in anchorage regulation of the Erk pathway. Expression of a constitutively activated PAK rescued signalling in suspended cells; this is interesting because a dominant-negative version of PAK1 reversed the rescue provided by dominant-negative PKA, suggesting that the two kinases were functionally linked. In further studies, we showed that PAK1 is a substrate for PKA and that PKA phosphorylation of PAK1 inhibits PAK activity.
The role of PAK in the Erk pathway is to provide permissive phosphorylations at S338 in Raf-1 and at S298 in MEK1 [9, 12] . The S338 phosphorylation is required for Raf activation, whereas the S298 phosphorylation promotes Raf-MEK association. Since cells are deprived of integrin-mediated anchorage, PKA is activated leading to phosphorylation and inhibition of PAK. Decreased PAK activity can prohibit the Erk pathway at both Raf-1 and MEK. An indication of the validity of this concept is seen with the use of a phosphomimetic mutant of Raf-1 (S338D). Expression of this protein can also partially rescue Erk signalling in suspended cells. However, anchorage regulation of the Erk pathway, as well as PKA regulation, probably involves more than just influencing the activity of PAK. Thus there are additional key phosphorylation sites on Raf-1 that are negatively regulated by PKA, such as S259 [18] . Finally, PKA also affects the organization of the actin cytoskeleton through the phosphorylation of VASP-family proteins [19] and other key cytoskeletal elements. The organization of actin filaments, particularly cortical actin, seems to also play an important modulatory role in regulating the Erk signalling pathway [20] .
In summary, PKA and PAK play important roles in controlling the Raf/MEK/Erk signalling module. The activity of PKA affects that of PAK and both are influenced by the state of integrin-mediated anchorage. In addition to its contribution to the regulation of anchorage-dependent RTK signalling, PKA seems to be important for another integrinmediated process, namely chemotactic cell migration [21] . Indeed, it is quite clear that integrins play a multifaceted role in the regulation of cell migration, as discussed in detail below.
Integrins and cell migration
The most obvious role for integrins in cell motility involves their ability to interface with the ECM and thus allow cells to grasp the substratum and move. Cell locomotion depends on a highly orchestrated set of events involving the polymerization and de-polymerization of actin filaments and the exertion of force through actinomyosin-mediated contraction [22, 23] . Inevitably, this complex process is regulated by multiple signalling mechanisms. Members of the Rho family of GTPases play a central role in the regulation of the actin cytoskeleton, with RhoA, Rac and CDC42 influencing stress fibres, lamellipodia and filopodia respectively [24] . In addition, however, many other signalling components influence the actin-myosin machinery, including focal adhesion kinase, Src kinase, the Erk pathway, the JNK pathway and PI3K (phosphoinositide 3-kinase) [25] [26] [27] [28] [29] [30] . Integrins modulate many of these signalling components; thus the role of integrins in cell movement includes a signalling aspect as well as a structural aspect (Figure 2) .
While screening for proteins that interact with integrin cytoplasmic domains using a two-hybrid assay, we found a novel protein that binds preferentially to the cytoplasmic tail of the integrin α5 subunit [31] . We termed this protein 'Nischarin', a Sanskrit word that connotes slowness of motion. The α5-binding site on Nischarin was mapped to a 100-amino-acid region near the N-terminus, whereas the Nischarin-interacting site in the α5 tail was found to be in a membrane-proximal region overlapping the conserved GFFKR sequence [32] . Although Nischarin binds to the α5 subunit, it is not found in focal adhesion sites, suggesting that Nischarin binds to integrins when they are not ligated by ECM proteins.
The amino acid sequence of Nischarin did not reveal any obvious similarity to known proteins nor did it suggest a function for this novel protein. Thus we began to explore the possible impacts of Nischarin on integrin-associated cell functions. We soon found that overexpression of Nischarin profoundly inhibited cell migration. Furthermore, when Nischarin was co-expressed with activated Rac, it blocked the ability of Rac to promote lamellipodia formation. This result suggested that Nischarin was blocking migration by negatively regulating some aspect of the Rac signalling pathway [31] .
Rac has a large number of downstream effectors and so it was important to define which downstream pathway was affected. This task was approached using the so-called 'effector domain mutants' of Rac; these mutants interact selectively with members of the set of downstream effectors of Rac [33] . Activated Rac has been shown to drive migration strongly in certain carcinoma cell lines [34] . Using this model, the effect of Nischarin was evaluated in carcinoma cells transfected with constitutively activated effector domain mutants of Rac1. Interestingly, Nischarin was capable of blocking migration driven by versions of Rac that could activate PAK and JNK, but not by Rac mutants that lacked this function (but still promoted migration) [35] . This result strongly suggested that Nischarin was affecting either the JNK kinase cascade or PAK kinases, both of which are known to play important roles in migration. Results of very recent studies indicate that Nischarin affects PAK signalling by directly binding to PAK and blocking its ability to phosphorylate substrates.
At present, we visualize Nischarin as a key negative regulator of cell migration through its action on PAKs. Nischarin may be delivered to the leading edge of the cells by association with unligated integrins. Once the integrins enter into adhesion sites, Nischarin is released, allowing it to interact with PAK and down-regulate PAK activity.
